Brii Biosciences Limited
HKEX:2137.HK
Overview | Financials
Company Name | Brii Biosciences Limited |
Symbol | 2137.HK |
Currency | HKD |
Price | 1.09 |
Market Cap | 796,966,580 |
Dividend Yield | 0% |
52-week-range | 0.85 - 3.5 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Dr. Zhi Hong Ph.D. |
Website | https://www.briibio.com |
An error occurred while fetching data.
About Brii Biosciences Limited
Brii Biosciences Limited engages in the development of medicines for the treatment of infectious and central nervous system diseases. The company develops BRII-778 and BRII-732, which are in phase I clinical trials for the treatment of HIV patients; BRII-179 and BRII-835, which are in Phase 2 to evaluate the combination
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD